摘要
目的评价国产重组人血小板生成素(rhTPO)用于系统性红斑狼疮(SLE)合并难治性血小板减少性紫癜的可行性及安全性。方法对12例SLE并难治性血小板减少性紫癜患者行国产rhTPO皮下注射,15 000 U/d,疗程14 d。检测用药前、用药后7、10、14 d及停药3个月后的血小板数,判定疗效及不良反应情况。结果用药前血小板计数为(14.3±5.2)×109/L,用药后7、10、14 d分别为(37.8±9.3)×109/L、(64.2±15.6)×109/L、(84.3±25.7)×109/L,与用药前相比,P均<0.01。停药后3个月血小板计数为(53.2±15.6)×109/L,与治疗前比较,P<0.01。总有效率为83.33%,仅2例出现轻微不良反应。结论rhTPO治疗SLE合并难治性血小板减少性紫癜疗效确切,且较为安全。
Objective To evaluate the feasibility and safety of recombinant human thrombopoietin （rhTPO） in the treatment of refractory thrombocytopenic purpura in patients with systemic lupus erythematosus （SLE）. Methods Twelve patients with SLE and refractory thrombocytopenie purpura were given 15 000 U/d rhTPO subcutaneously once daily for 14 days. The platelet count before treatment and 7,10,14 ds after treatment and 3 months after drug withdrawal were determined, the efficacy and adverse reactions were observed. Results The platelet count before treatment was （ 14.3 ± 5.2） × 10^9/L, 7,10,14 ds after treatment were （37.8 ± 9.3 ） × 10^9/L, （64.2 ± 15.6） × 10^9/L, （ 84.3 ± 25.7） × 10^9/L, compared with the level before treatment,P 〈 0.01. Three months after drug withdrawal, the platelet count was （53.2 ± 15.6） × 10^9/L, compared with the level before treatment, P 〈 0.01. The over all responserate was 83.3% ,2 patients showed mild adverse effects. Conclusion rhTPO is effective for the treatment of refractory thrombocytopenie purpura in patients with SLE, and also is more safety.
出处
《山东医药》
CAS
北大核心
2010年第11期19-20,共2页
Shandong Medical Journal
作者简介
通讯作者
